News
-
Since October 1, 2010, Vectura’s financial performance has exceeded the board’s expectations, according to the company’s interim management statement. Chief Executive Chris Blackwell attributes the improved performance to a restructured R&D program and says that… Read more . . .
-
Scott R. Ward has been named Chairman of the Board of Directors by MAP Pharmaceuticals, replacing Staven A. Elms. MAP plans to submit an NDA for its Levadex inhaled ergotamine for the treatment of migraine… Read more . . .
-
North Carolina specialty pharma company Inspire Pharmaceuticals has announced that it is cutting 27% of its workforce (65 jobs) after its denufosol inhalation solution for the treatment of cystic fibrosis failed a Phase 3 trial.… Read more . . .
-
A group of investors led by LSP Life Sciences Partners of Amsterdam has put together €5 million that device company Activaero will use for continued development of its inhalation systems. Activaero recently initiated clinical studies… Read more . . .
-
A review study published in The Cochrane Library finds that inhaled epinephrine provides significant relief of croup symptoms in children within 30 minutes compared to placebo. The review included 8 studies involving 225 children. Read… Read more . . .
-
According to MannKind Corporation, it remains committed to gaining approval for its Afrezza inhaled insulin despite continuing requests from the FDA for additional data. The company announced that it is restructuring in order to focus… Read more . . .
-
Teva’s Qnaze beclomethasone nasal aerosol has met all efficacy endpoints in a Phase III trial. The study involved 470 patients with perennial allergic rhinitis. After 6 weeks of treatment, patients using the product experienced significant… Read more . . .
-
Pharmaxis has received TGA approval to market its Bronchitol inhaled dry powder mannitol in Australia for the treatment of cystic fibrosis. The approval is for patients over 6 years old. Bronchitol received orphan drug designation… Read more . . .
-
According to Teva, its worldwide sales of respiratory drugs, including the Pro-Air albuterol and QVAR beclomethasone inhalers, were down 3% from 2009, to $875 million. Of that amount, $556 million is attributable to sales in… Read more . . .
-
Isis Pharmaceuticals has reportedly closed down Altair Therapeutics, which it had spun off in 2007 to develop AIR645, an inhaled IL-4 and IL-13 inhibitor for the treatment of asthma. The drug, which was the only… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland